# CinDome Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cindome-pharma

- Industry: Pharmaceuticals
- Headquarters: Cincinnati, US
- Website: www.cindome.com
- Total disclosed funding: $29M
- Latest round: Series B (May 16, 2024)
- Investors on record: 2

## About

Established in 2015 by CEO Jon Isaacsohn  and based in Ohio, US, CinDome Pharma, Inc. is conducting research and developing the medication deudomperidone, which is used to treat persistent gastroparesis. In May 2024, CinDome Pharma, Inc. raised USD 40 million in Series B funding from investors Perceptive Advisors and CinRx Pharma.

CinDome's primary pharmaceutical focus is the development of CIN-102, an engineered formulation of domperidone intended for the treatment of gastroparesis.  This chronic condition causes delayed stomach emptying, leading to nausea, vomiting, and abdominal pain. CinDome Pharma's product pipeline includes CIN-109 and CIN-110: monotherapies targeting obesity through GDF-15 and PYY 3-36 analogs. CIN-209 and CIN-210: Combination treatments for obesity, leveraging dual agonists of GDF-15/GLP-1 and PYY 3-36/GLP-1. CIN-102: A dopamine 2/3 antagonist for gastroparesis with prokinetic and antiemetic effects. CIN-103: A formulation for IBS-D aimed at enhancing therapeutic exposure. CIN-108: An oncology treatment targeting defective cullin neddylation 1 (DCN1). TTP399: An adjunct therapy for type 1 diabetes. Neurodegenerative therapies: under development by Retromer Therapeutics.

The company will use the May 2024 funding to further develop deudomperidone.

## Funding rounds

- Series B, May 16, 2024, $29M — Perceptive Advisors, CinRx Pharma, LLC

## Investors

- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- CinRx Pharma, LLC — Series B